2 results
Approved WMORecruiting
To evaluate whether a faecal calprotectin guided strategy of anti-TNF dosing interval lengthening is non-inferior in maintaining remission in patients with IBD compared with an unchanged dosing interval.
Approved WMORecruiting
Study CA001-050 is a Phase 2 randomized, open label, multicenter clinical study designed to assess the safety and tolerability, of treatment with MS-986012 in combination with chemotherapy (carboplatin and etoposide) and nivolumab when administered…